Understand the source comparison
AICAR vs GW501516
GW501516 is the other compound from the Salk Institute study. It works through PPARdelta activation rather than AMPK. While both are classified as exercise mimetics, they target different molecular pathways. In the original study, GW501516 combined with exerci
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GW501516 is the other compound from the Salk Institute study. It works through PPARdelta activation rather than AMPK. While both are classified as exercise mimetics, they target different molecular pathways.
- In the original study, GW501516 combined with exercise produced a 70% endurance improvement, greater than AICAR alone at 44%. However, GW501516 required exercise to achieve its full effect, while AICAR worked without exercise. GW501516 alone was insufficient.
- GW501516 carries its own significant safety concerns, including promotion of cancer growth in some animal models. The compound has never been approved for human use and was dropped from clinical development.
- The two compounds work through somewhat overlapping but distinct gene expression programs. Simultaneous treatment created a gene expression signature in muscle that shared about 40% of the genes with the combined GW501516 plus exercise signature. This suggests potential synergy, though the combined safety profile remains unknown.